Tasly Pharmaceutical Group Co., Ltd (SHA:600535)
14.67
-0.11 (-0.74%)
Feb 13, 2026, 3:00 PM CST
SHA:600535 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | - | 2,994 | 4,451 | 3,119 | 2,304 |
Trading Asset Securities | - | 524.72 | 300.71 | 1,125 | 1,487 |
Cash & Short-Term Investments | 3,489 | 3,518 | 4,751 | 4,244 | 3,791 |
Cash Growth | -0.83% | -25.95% | 11.95% | 11.95% | 78.94% |
Accounts Receivable | - | 1,966 | 2,131 | 3,348 | 3,796 |
Other Receivables | - | 23.06 | 11.49 | 8.98 | 9.47 |
Receivables | - | 1,989 | 2,142 | 3,357 | 3,805 |
Inventory | - | 1,712 | 1,748 | 1,532 | 1,548 |
Other Current Assets | - | 91.72 | 91.43 | 127.08 | 105 |
Total Current Assets | - | 7,311 | 8,733 | 9,260 | 9,249 |
Property, Plant & Equipment | - | 3,648 | 3,769 | 3,883 | 4,088 |
Long-Term Investments | - | 1,821 | 2,054 | 1,511 | 1,229 |
Goodwill | - | - | 15.88 | 15.88 | 167.08 |
Other Intangible Assets | - | 604.17 | 573.64 | 459.43 | 474.54 |
Long-Term Deferred Tax Assets | - | 53.17 | 50 | 88.29 | 60.79 |
Long-Term Deferred Charges | - | 1,466 | 1,476 | 1,157 | 1,193 |
Other Long-Term Assets | - | 72.54 | 43.14 | 102.08 | 79.68 |
Total Assets | - | 14,976 | 16,714 | 16,477 | 16,542 |
Accounts Payable | - | 606.81 | 572.73 | 887.77 | 728.58 |
Accrued Expenses | - | 171.05 | 178.38 | 242.79 | 213.15 |
Short-Term Debt | - | 710.95 | 814.63 | 201.77 | 188.79 |
Current Portion of Long-Term Debt | - | 586.83 | 462.74 | 475.21 | 343.33 |
Current Portion of Leases | - | 47.84 | 58.54 | 53.98 | 55.67 |
Current Income Taxes Payable | - | 57.78 | 18.04 | 84.62 | 108.09 |
Current Unearned Revenue | - | 69.85 | 91.62 | 92.35 | 68.33 |
Other Current Liabilities | - | 98.58 | 172.88 | 108.72 | 149.12 |
Total Current Liabilities | - | 2,350 | 2,370 | 2,147 | 1,855 |
Long-Term Debt | - | 253.76 | 1,414 | 1,376 | 1,034 |
Long-Term Leases | - | 67.97 | 81.52 | 75.31 | 81.63 |
Long-Term Unearned Revenue | - | 193.29 | 159.02 | 177.79 | 214.57 |
Long-Term Deferred Tax Liabilities | - | 0.4 | 0.11 | 22.87 | 42.18 |
Total Liabilities | - | 2,865 | 4,024 | 3,799 | 3,228 |
Common Stock | - | 1,494 | 1,500 | 1,500 | 1,513 |
Additional Paid-In Capital | - | 458.96 | 958.08 | 1,457 | 1,530 |
Retained Earnings | - | 9,898 | 9,929 | 9,351 | 10,222 |
Treasury Stock | - | - | -105.98 | -105.98 | -251.29 |
Comprehensive Income & Other | - | 52.22 | 88 | 211.58 | -32.19 |
Total Common Equity | 12,304 | 11,903 | 12,368 | 12,412 | 12,981 |
Minority Interest | - | 207.86 | 321.59 | 265.12 | 332.56 |
Shareholders' Equity | 12,500 | 12,111 | 12,690 | 12,678 | 13,314 |
Total Liabilities & Equity | - | 14,976 | 16,714 | 16,477 | 16,542 |
Total Debt | 857.03 | 1,667 | 2,831 | 2,182 | 1,704 |
Net Cash (Debt) | 2,632 | 1,851 | 1,920 | 2,062 | 2,088 |
Net Cash Growth | 42.20% | -3.59% | -6.89% | -1.23% | - |
Net Cash Per Share | 1.76 | 1.24 | 1.29 | 1.40 | 1.39 |
Filing Date Shares Outstanding | 1,494 | 1,494 | 1,494 | 1,494 | 1,499 |
Total Common Shares Outstanding | 1,494 | 1,494 | 1,494 | 1,494 | 1,499 |
Working Capital | - | 4,961 | 6,363 | 7,113 | 7,394 |
Book Value Per Share | 8.24 | 7.97 | 8.28 | 8.31 | 8.66 |
Tangible Book Value | 11,525 | 11,299 | 11,779 | 11,937 | 12,340 |
Tangible Book Value Per Share | 7.71 | 7.56 | 7.88 | 7.99 | 8.23 |
Buildings | - | 3,517 | 3,505 | 3,490 | 3,398 |
Machinery | - | 3,763 | 3,625 | 3,472 | 3,340 |
Construction In Progress | - | 221.76 | 153.87 | 102.96 | 167.85 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.